Core Viewpoint - The company reported a revenue of RMB 393.4 million for the six months ending June 30, 2025, representing an 8.4% year-on-year increase, while the net profit attributable to the parent company decreased by 66.7% to RMB 20.5 million [1][2]. Financial Performance - Revenue for the period was RMB 393.4 million, up from RMB 362.9 million in the same period last year [2]. - Gross profit remained relatively stable at RMB 282.6 million, compared to RMB 282.6 million in the previous year [2]. - The sales cost increased significantly to RMB 110.8 million from RMB 80.3 million, indicating a rise in operational expenses [2]. - Other income and gains decreased sharply to RMB 2.6 million from RMB 36.1 million [2]. - Research and development costs were reduced to RMB 58.6 million from RMB 85.8 million, reflecting a strategic focus on cost management [2]. - Administrative expenses slightly decreased to RMB 23.2 million from RMB 24.3 million [2]. - Selling and distribution expenses increased to RMB 159.8 million from RMB 134.2 million, indicating higher marketing efforts [2]. - Financial costs rose to RMB 19.5 million from RMB 12.6 million, impacting overall profitability [2]. Profitability Metrics - The profit before tax was RMB 20.5 million, down from RMB 61.7 million in the previous year [2]. - Basic earnings per share decreased to RMB 0.04 from RMB 0.12, reflecting the decline in net profit [2]. - Total comprehensive income for the period was RMB 20.4 million, significantly lower than RMB 61.6 million from the previous year [2].
博安生物：中期归母净利润2051.4万元，同比减少66.7%